Search - tctmd.com

Displaying 21 - 40 of 68

Sort: Relevancy | Date

Presentation ACC 2023

Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, a Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

Presenter: Christie Ballantyne

March 05, 2023

Presentation AHA 2022

Reduction of Lipoprotein(a) With Small Interfering RNA: Results of the OCEAN(a)-DOSE (TIMI 67) Trial

Presenter: Michelle L. O’Donoghue

November 07, 2022

Presentation TCT 2022

TCT 577: Lipoprotein (a) and Intracoronary Imaging After Intensive Statin Treatment

Presenter: Shingo Minatoguchi

September 19, 2022

Presentation ACC 2022

The PACMAN AMI Randomized Clinical Trial

Presenter: Lorenz Räber

April 04, 2022

Presentation ACC 2022

TRANSLATE-TIMI 70

Presenter: Brian Bergmark

April 04, 2022

Presentation Controversies and Advances 2021

What Diet is Best for Cardiovascular Health?

Presenter: Kim Allan Williams, Sr.

December 03, 2021

Presentation Controversies and Advances 2021

EPA Fish Oil: Who Should Receive It?

Presenter: Peter P. Toth

December 03, 2021

Presentation Controversies and Advances 2021

Pathways for Inflammation in Athero-thrombosis Focus on Inflammasome

Presenter: P. K. Shah

December 03, 2021

Presentation ACC 2020

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

Presenter: Frederick Raal

March 30, 2020

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

Presentation ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

Presentation AHA 2018

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Presenter: Sotirios Tsimikas

November 11, 2018

Presentation EAS 2018

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Presenter: Michelle L. O’Donoghue

May 07, 2018

Presentation EAS 2018

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Presenter: Brian A. Ference

May 07, 2018

Presentation ACC 2018

The ODYSSEY OUTCOMES Trial: Topline Results Alirocumab in Patients After Acute Coronary Syndrome

Presenter: Philippe Gabriel Steg

March 10, 2018

Presentation Controversies and Advances 2017

Does IMPROVE-IT and FOURIER. Confirm or Refute the LDL Hypothesis?

Presenter: Sanjay Kaul

November 16, 2017

Presentation Controversies and Advances 2017

Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It?

Presenter: Sanjay Kaul

November 16, 2017

Presentation

Global Geographic Variation in Patient Characteristics in PCI Clinical Trials

September 15, 2017

Presentation ESC 2017

Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South Africa, Middle East and China

Presenter: Anselm K. Gitt

August 30, 2017

Presentation ESC 2017

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano

August 28, 2017

Advertisement

Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, a Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

Reduction of Lipoprotein(a) With Small Interfering RNA: Results of the OCEAN(a)-DOSE (TIMI 67) Trial

TCT 577: Lipoprotein (a) and Intracoronary Imaging After Intensive Statin Treatment

The PACMAN AMI Randomized Clinical Trial

TRANSLATE-TIMI 70

What Diet is Best for Cardiovascular Health?

EPA Fish Oil: Who Should Receive It?

Pathways for Inflammation in Athero-thrombosis Focus on Inflammasome

Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

The ODYSSEY OUTCOMES Trial: Topline Results Alirocumab in Patients After Acute Coronary Syndrome

Does IMPROVE-IT and FOURIER. Confirm or Refute the LDL Hypothesis?

Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It?

Global Geographic Variation in Patient Characteristics in PCI Clinical Trials

Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South Africa, Middle East and China

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content